Bladder Cancer Tumor Homograft Models

MuPrime tumor homograft models provide an ideal platform to investigate your novel surrogate or cross-reactive agent with competent murine immunity, and the presence of relevant mutations for bladder cancer such as PTEN loss and KRAS activation. Our bladder cancer tumor homografts combine the predictive power of GEMM with the operational symplicity required for pharmacology studies.